Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma

Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma

Introduction: Immune check point inhibitors have recently entered the armamentarium of advanced hepatocellular carcinoma (HCC) treatment. Among them, the combination of atezolizumab plus bevacizumab has pushed it a step forward; however, a number of patients still present primary non-responses witho...

Full description

Bibliographic Details
Main Authors: Catia Giovannini, Fabrizia Suzzi, Francesco Tovoli, Mariangela Bruccoleri, Mariarosaria Marseglia, Eleonora Alimenti, Francesca Fornari, Massimo Iavarone, Fabio Piscaglia, Laura Gramantieri
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
HCC
immunotherapy
granulocytes
PD1
flow cytometry
Online Access:https://www.mdpi.com/2072-6694/15/6/1661

Internet

https://www.mdpi.com/2072-6694/15/6/1661

Similar Items